Literature DB >> 31375946

ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer.

Daniela Zanini1,2, Leandro Henrique Manfredi3, Luana Paula Pelinson4, Victor Camera Pimentel4, Andréia Machado Cardoso5,4, Viviane do Carmo Araújo Gonçalves4, Cláudia Bertoncelli Dos Santos4, Jessié Martins Gutierres4, Vera Maria Morsch4, Daniela Bitencourt Rosa Leal4, Maria Rosa Chitolina Schetinger4.   

Abstract

Cigarette smoking is directly associated with lung cancer. Non-small cell lung carcinoma (NSCLC) represents approximately 80% from all types of lung cancer. This latter is hard to diagnose and to treat due to the lack of symptoms in early stages of the disease. The aim of this study was to evaluate ADA activity and the expression of P2X7, A1, and A2A receptors and in lymphocytes. In addition, the profile of pro-inflammatory and anti-inflammatory cytokines serum levels of patients with lung cancer in advanced stage was evaluated. Patients (n = 13) previously treated for lung cancer at stage IV (UICC) with chemotherapy had their blood collected. Cancer patients showed a decrease in ADA activity and an increase in A1 receptor expression in lymphocytes when compared to the control group. Moreover, patients exhibited an increase in IL-6 and TNF-α, while IL-17 and INF-ϒ serum levels were lower in patients with lung cancer. The decreased ADA activity and the increase in A1 receptor expression may contribute to adenosine pro-tumor effects by increasing IL-6 and TNF-α and decreasing IL-17 and INF-γ serum levels. Our data show an indirect evidence that purinergic signaling may have a role in promoting a profile of cytokines levels that favors tumor progression.

Entities:  

Keywords:  ADA; Adenosine receptor; IL-6; Lung cancer Inflammation; P2X7 receptor; TNF-α

Mesh:

Substances:

Year:  2019        PMID: 31375946     DOI: 10.1007/s12032-019-1301-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  6 in total

1.  Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma.

Authors:  Yukui Gao; Guixin Wang; Yanzhuo Chen; Mingpeng Zhang; Wenlong Gao; Zhiqun Shang; Yuanjie Niu
Journal:  Front Genet       Date:  2022-04-25       Impact factor: 4.772

2.  Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion.

Authors:  Zenghua Ren; Ling Xu
Journal:  Clinics (Sao Paulo)       Date:  2021-04-26       Impact factor: 2.365

Review 3.  Novel possibility for cutaneous melanoma treatment by means of rosmarinic acid action on purinergic signaling.

Authors:  Gilnei Bruno da Silva; Milena Ayumi Yamauchi; Daniela Zanini; Margarete Dulce Bagatini
Journal:  Purinergic Signal       Date:  2021-11-05       Impact factor: 3.765

4.  High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.

Authors:  Gilnei Bruno da Silva; Daiane Manica; Alana Patrícia da Silva; Greicy Cristine Kosvoski; Marceli Hanauer; Charles Elias Assmann; Júlia Leão Batista Simões; Micheli Mainardi Pillat; Jéssica Dotto de Lara; Filomena Marafon; Amanda Gollo Bertollo; Maiqueli E D Mingoti; Jullye Gavioli; Gislaine Zilli Réus; Gabriela Gonçalves de Oliveira; Zuleide Maria Ignácio; Margarete Dulce Bagatini
Journal:  J Mol Med (Berl)       Date:  2022-03-06       Impact factor: 4.599

5.  A Prognostic Model Based on Six Metabolism-Related Genes in Colorectal Cancer.

Authors:  Yuan-Lin Sun; Yang Zhang; Yu-Chen Guo; Zi-Hao Yang; Yue-Chao Xu
Journal:  Biomed Res Int       Date:  2020-08-31       Impact factor: 3.411

Review 6.  Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer.

Authors:  Galina Zhulai; Eugenia Oleinik; Mikhail Shibaev; Kirill Ignatev
Journal:  Biomolecules       Date:  2022-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.